Stockscreener 앱 받기
10.06
36.77%
-5.85
시간 외 거래:
10.09
0.03
+0.30%
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - MedCity News
Kura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely Bullish - Asianet Newsable
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Kura Oncology: A Contender In The Field Of Precision Medicine - Seeking Alpha
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects By Investing.com - Investing.com Canada
Buy rating reiterated for Kura Oncology stock, analyst raises target on ziftomenib advancements - Investing.com Canada
Biotech Collapses 27% After Slamming The Door On A Takeover - Investor's Business Daily
Kura Oncology (NASDAQ:KURA) Price Target Raised to $37.00 - MarketBeat
Kura Oncology partners Kyowa Kirin to advance AML treatment - Yahoo! Voices
Kura and Kyowa Kirin sign ziftomenib deal - The Pharma Letter
Kura partners with Kyowa Kirin to advance AML treatment - Pharmaceutical Technology
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - Barchart
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 - Investing.com
Kura Oncology inks global deal with Kyowa Kirin By Investing.com - Investing.com UK
Kura Oncology Shares Fall 14% on Plans for Cancer-Drug Collaboration - MarketWatch
Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - MSN
KURAKura Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Kura Oncology (NASDAQ:KURA) Cut to Sell at StockNews.com - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Kura Oncology stock gains spotlight amid Revuforj's FDA approval By Investing.com - Investing.com UK
Objective long/short (KURA) Report - Stock Traders Daily
Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology I - GuruFocus.com
Kura Oncology (NASDAQ:KURA) Raised to “Hold” at StockNews.com - Defense World
Kura Oncology's SWOT analysis: ziftomenib drives stock potential amid AML market - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
FY2026 EPS Estimate for Kura Oncology Lifted by Analyst - MarketBeat
HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $28.83 - MarketBeat
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's What Happened - MarketBeat
Kura Oncology: Q3 Earnings Snapshot - San Francisco Chronicle
Kura Oncology Reports Third Quarter 2024 Financial Results - The Manila Times
Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright - MarketBeat
When the Price of (KURA) Talks, People Listen - Stock Traders Daily
Kura Oncology to present AML trial data at ASH meeting - Investing.com
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - The Manila Times
Kura Oncology, Inc. Announces to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - Marketscreener.com
Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Kura Oncology to Report Third Quarter 2024 Financial Results - The Manila Times
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
UBS Group Initiates Coverage on Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) Receives New Coverage from Analysts at UBS Group - MarketBeat
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of - The Bakersfield Californian
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - StockTitan
Kura Oncology Enters Oversold Territory (KURA) - Nasdaq
Lifesci Capital Upgrades Kura Oncology (NASDAQ:KURA) to "Strong-Buy" - MarketBeat
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - The Manila Times
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September - MarketBeat
0.93%
3.55%
자본화:
|
볼륨(24시간):